GSMS Niacin Extended-Release Tablets Recall
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Golden State Medical Supply Inc. is recalling 2,961 bottles of Niacin Extended-Release Tablets, USP 1,000 mg due to failed dissolution specifications.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on July 27, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened
Golden State Medical Supply Inc. initiated a voluntary recall of specific lots of NIACIN EXTENDED-RELEASE TABLETS, USP, 1,000 MG after 12-month long-term stability testing showed the product was out of specification for stage 3 dissolution at the 24-hour timepoint.
Which Products Are Affected
The recall covers GSMS Incorporated, NIACIN EXTENDED-RELEASE TABLETS, USP, 1,000 MG, 90 tablets, Rx only (NDC 51407-268-90), packaged by GSMS Incorporated, Camarillo, CA. Affected lots are GS065128, GS065844, GS066695, GS067432, GS067993, all expiring 01/31/2027. A total of 2,961 bottles were distributed within the U.S. market. The recall number is D-0587-2026.
What You Should Do
Consumers with questions should contact their healthcare provider or pharmacist regarding the affected product.
Why This Matters
This Class II recall addresses a product that may not meet dissolution specifications, potentially affecting drug release performance.
Source
FDA recall D-0587-2026; https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,072 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to July 27, 2026.
Frequently Asked Questions
Common questions about this FDA recall.